We could not find any results for:
Make sure your spelling is correct or try broadening your search.
The current GILD market cap is 83.44B. The company's latest EPS is USD 4.5474 and P/E is 14.80.
Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Revenue | 7.04B | 7.39B | 6.35B | 6.6B | 7.05B |
Operating Income | 2.84B | 2.27B | 1.7B | 1.67B | 2.63B |
Net Income | 1.79B | 1.64B | 1.01B | 1.05B | 2.18B |
Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Revenue | 22.45B | 24.69B | 27.31B | 27.28B | 27.12B |
Operating Income | 4.29B | 4.07B | 9.92B | 7.33B | 7.61B |
Net Income | 5.39B | 123M | 6.23B | 4.59B | 5.67B |
Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Assets | 62.56B | 63.17B | 61.88B | 62.34B | 62.37B |
Total Liabilities | 41.5B | 41.96B | 40.94B | 41.24B | 40.13B |
Total Equity | 21.06B | 21.21B | 20.94B | 21.09B | 22.24B |
Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Assets | 61.63B | 68.41B | 67.95B | 63.17B | 62.13B |
Total Liabilities | 38.98B | 50.19B | 46.89B | 41.96B | 39.38B |
Total Equity | 22.65B | 18.22B | 21.06B | 21.21B | 22.75B |
Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Operating | 6.51B | 9.07B | 1.75B | 4.08B | 5.84B |
Investing | -2.09B | -2.47B | -826M | -1.31B | -1.54B |
Financing | -4.92B | -6.47B | -1.41B | -2.51B | -4.03B |
Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Operating | 9.14B | 8.17B | 11.38B | 9.07B | 8.01B |
Investing | -7.82B | -14.62B | -3.13B | -2.47B | -2.27B |
Financing | -7.63B | 770M | -8.88B | -6.47B | -5.13B |
Market Cap | 83.44B |
Price to Earnings Ratio | 14.80 |
Price to Sales Ratio | 3.09 |
Price to Cash Ratio | 13.78 |
Price to Book Ratio | 3.68 |
Dividend Yield | 4.51% |
Shares Outstanding | 1.25B |
Average Volume (1 week) | 6.6M |
Average Volume (1 Month) | 6.39M |
52 Week Change | -22.67% |
52 Week High | 87.865 |
52 Week Low | 65.90 |
Spread (Intraday) | 0.01 (0.01%) |
Company Name | Gilead Sciences Inc |
Address |
1209 orange street wilmington, delaware 19801 |
Website | https://www.gilead.com |
Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions